Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “market perform” rating reaffirmed by analysts at Leerink Swann in a report released on Wednesday. They presently have a $87.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $82.00. Leerink Swann’s price objective points to a potential upside of 5.72% from the company’s previous close.

A number of other research firms have also commented on GILD. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a research note on Monday, September 4th. Finally, Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research note on Wednesday, September 6th. Eleven analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $84.29.

Shares of Gilead Sciences (GILD) traded down 0.30% during midday trading on Wednesday, hitting $82.04. The stock had a trading volume of 3,247,368 shares. The firm has a 50 day moving average of $77.54 and a 200-day moving average of $70.38. The company has a market cap of $107.14 billion, a P/E ratio of 8.91 and a beta of 1.19. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the business earned $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts forecast that Gilead Sciences will post $8.78 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/20/gilead-sciences-inc-gild-earns-market-perform-rating-from-leerink-swann.html.

In related news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 466,819 shares of company stock worth $36,740,240 in the last quarter. Insiders own 1.30% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its holdings in shares of Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC increased its holdings in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. increased its holdings in shares of Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. bought a new position in shares of Gilead Sciences during the 1st quarter worth about $143,000. Hedge funds and other institutional investors own 73.97% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.